Research published in the Journal of Oncology Practice found that factors unrelated to the individual patient accounted for the majority of variation in the cost of radiation therapy for breast, prostate, and lung cancer patients.
A study published in the Journal of Oncology Practice by researchers at the Moores Cancer Center at the University of San Diego has identified significant variability in the cost of radiation therapy among Medicare enrollees.
“Understanding why costs vary for radiation therapy helps policy makers evaluate the efficiency of the current fee-for-service Medicare reimbursement system. Such insights are likely to shape policy reforms in the near-future,” said Anthony Paravati, MD, first author of the study.
Using Medicare reimbursement amounts from the SEER database for radiation therapy among more than 55,000 breast, lung, or prostate cancer patients diagnosed between 2004 and 2009, the researchers examined the extent to which the tumor type, radiation therapy provider, or the patient influence the cost of radiation treatment. The results of the multivariable regression analysis were surprising. The median cost of a single course of radiation therapy was $8600 ($7300 to $10,300) for breast cancer, $9000 ($7500 to $11,100) for lung cancer, and $18,000 ($11,300 to $25,000) for prostate cancer. The authors found that the tumor type and patient characteristics influenced less than 3% of the cost. A majority of the variability, the authors found, stemmed from practice type, geographical location of the treatment center, and the radiation provider.
“Factors unrelated to the individual patient accounted for the majority of variation in the cost of radiation therapy, suggesting potential inefficiency in health care expenditure,” the authors write. They suggest identifying whether this variability translates into improved patient outcomes and quality of care for further evaluation of current reimbursement practices.
Persistence Pays Off With Zanubrutinib: A Challenging CLL Case With a Prior BTK Inhibitor Failure
May 10th 2024The case of a 77-year-old woman with a long chronic lymphocytic leukemia (CLL) history illustrates the novel use of zanubrutinib as a potential option for some patients who have failed first-generation Bruton tyrosine kinase (BTK) inhibitors and venetoclax.
Read More
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
CMS Medicare Final Rule: Advancing Benefits, Competition, and Consumer Protection
May 7th 2024On this episode of Managed Care Cast, we're talking with Karen Iapoce, senior director of government products and programs at ZeOmega, about the recent CMS final rule on Medicare Part D and Medicare Advantage.
Listen